Difference between revisions of "Comment Resolutions"
Jump to navigation
Jump to search
(11 intermediate revisions by 2 users not shown) | |||
Line 69: | Line 69: | ||
| [[Media:QIBA MSK BC Public Comment Resolutions.pdf| Public Comment Resolutions]] | | [[Media:QIBA MSK BC Public Comment Resolutions.pdf| Public Comment Resolutions]] | ||
|- | |- | ||
− | | [[Media:QIBA DCE- | + | | [[Media:QIBA DCE-Profile - v2.0 - Consensus Document.pdf|MR DCE-MRI Quantification (DCEMRI-Q) 2023-12-06]] |
− | | | + | | Consensus |
− | | | + | | 2023.12-06 |
− | | | + | | [[Media:QIBA DCE-MRI Public Comment Resolutions.pdf| Public Comment Resolutions]] |
|- | |- | ||
| [[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf| MR Elastography of the Liver 2022-02-14]] | | [[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf| MR Elastography of the Liver 2022-02-14]] | ||
Line 84: | Line 84: | ||
| [[Media:QIBA DWI-MR Clinical Feasibility Resolutions.pdf| Clinically Feasible Resolutions 2022-12-15]] | | [[Media:QIBA DWI-MR Clinical Feasibility Resolutions.pdf| Clinically Feasible Resolutions 2022-12-15]] | ||
|- | |- | ||
− | |MR MRI-Based Proton Density Fat Fraction (PDFF) of the Liver | + | | [[Media:QIBA PDFF Profile Stage2 FINAL.pdf| MR MRI-Based Proton Density Fat Fraction (PDFF) of the Liver 2023-12-04]] |
− | | | + | |Consensus |
|2023.09.08 | |2023.09.08 | ||
− | | | + | | [[Media:QIBA PDFF Public Comment Resolutions.pdf| Public Comment Resolutions 2023-11-14]] |
|- | |- | ||
| colspan="4" align="center" style="background:#dddddd" | '''PET/NM Profiles''' | | colspan="4" align="center" style="background:#dddddd" | '''PET/NM Profiles''' | ||
Line 127: | Line 127: | ||
| 2023.02.07 | | 2023.02.07 | ||
| [[Media:QIBA US SWS Comments 2023-02-20-v2.xlsx| Clinically Feasible Comment Resolutions 2023-02-20]] | | [[Media:QIBA US SWS Comments 2023-02-20-v2.xlsx| Clinically Feasible Comment Resolutions 2023-02-20]] | ||
+ | |- | ||
+ | | [[Media:QIBA US SWS Profile 2023-02-07.pdf|US Shear Wave Speed for Liver Fibrosis 2023-02-07, marked-up version]] | ||
+ | | Clinically Feasible | ||
+ | | 2023.12.13 | ||
+ | | [[Media:2023 12 13 SWS BC QIBA Technical Confirmation Resolutions.xlsx| Clinically Feasible Comment Resolutions 2023-12-13]] | ||
+ | |- | ||
+ | | [[Media:SWS Profile Final Candidate February 07 2023 CLEAN.pdf|US Shear Wave Speed for Liver Fibrosis 2023-02-07, clean version]] | ||
+ | | Clinically Feasible | ||
+ | | 2023.12.13 | ||
+ | | [[Media:2023 12 13 SWS BC QIBA Technical Confirmation Resolutions.xlsx| Clinically Feasible Comment Resolutions 2023-12-13]] | ||
+ | |- | ||
+ | | [[Media:QIBA US VBF Profile 2023-12-13-tracked-changes.pdf|US Volume Blood Flow (VBF) Profile 2023-12-13 (tracked changes)]] | ||
+ | | Consensus | ||
+ | | 2023.12.13 | ||
+ | | [[Media:2023 12 13 VBF BC QIBA Consensus Confirmation Resolutions.xlsx| Consensus Comment Resolutions 2023-12-13]] | ||
|- | |- | ||
|} | |} |
Latest revision as of 14:53, 21 December 2023
Comments received during Public Comment, Clinically Feasible (formerly Technical) Confirmation, or during a Profile ballot, are reviewed by the originating Biomarker Committee.
Per the QIBA Process, committees record how each collected comment was resolved and those resolutions are posted here.